MedTrace Logo

Global Prevalence of ATTR-CM in Participants With HFpEF

NCT04424914 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 347

Last updated 2024-07-19

Study results available
· View outcomes & findings →

Summary

This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population \[participants with heart failure with preserved ejection fraction (HFpEF)\].

Conditions

Interventions

DIAGNOSTIC_TEST

Scintigraphy

scintigraphy

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-30
Primary Completion
2023-06-02
Completion
2023-06-02

Countries

  • United States
  • Canada
  • France
  • Italy
  • Japan
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04424914 on ClinicalTrials.gov